Search Results - "Gill, Sonja J"

Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma by Gill, Sonja J, Travers, Jon, Pshenichnaya, Irina, Kogera, Fiona A, Barthorpe, Syd, Mironenko, Tatiana, Richardson, Laura, Benes, Cyril H, Stratton, Michael R, McDermott, Ultan, Jackson, Stephen P, Garnett, Mathew J

“…Ewing's sarcoma is a malignant pediatric bone tumor with a poor prognosis for patients with metastatic or recurrent disease. Ewing's sarcoma cells are acutely…”
Get full text

Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper by Illuzzi, Giuditta, Staniszewska, Anna D, Gill, Sonja J, Pike, Andy, McWilliams, Lisa, Critchlow, Susan E, Cronin, Anna, Fawell, Stephen, Hawthorne, Glen, Jamal, Kunzah, Johannes, Jeffrey, Leonard, Emilyanne, Macdonald, Ruth, Maglennon, Gareth, Nikkilä, Jenni, O'Connor, Mark J, Smith, Aaron, Southgate, Harriet, Wilson, Joanne, Yates, James, Cosulich, Sabina, Leo, Elisabetta

“…We hypothesized that inhibition and trapping of PARP1 alone would be sufficient to achieve antitumor activity. In particular, we aimed to achieve selectivity…”
Get full text

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}- N -methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs by Johannes, Jeffrey W, Balazs, Amber, Barratt, Derek, Bista, Michal, Chuba, Matthew D, Cosulich, Sabina, Critchlow, Susan E, Degorce, Sébastien L, Di Fruscia, Paolo, Edmondson, Scott D, Embrey, Kevin, Fawell, Stephen, Ghosh, Avipsa, Gill, Sonja J, Gunnarsson, Anders, Hande, Sudhir M, Heightman, Tom D, Hemsley, Paul, Illuzzi, Giuditta, Lane, Jordan, Larner, Carrie, Leo, Elisabetta, Liu, Lina, Madin, Andrew, Martin, Scott, McWilliams, Lisa, O'Connor, Mark J, Orme, Jonathan P, Pachl, Fiona, Packer, Martin J, Pei, Xiaohui, Pike, Andrew, Schimpl, Marianne, She, Hongyao, Staniszewska, Anna D, Talbot, Verity, Underwood, Elizabeth, Varnes, Jeffrey G, Xue, Lin, Yao, Tieguang, Zhang, Ke, Zhang, Andrew X, Zheng, Xiaolan

“…Poly-ADP-ribose-polymerase (PARP) inhibitors have achieved regulatory approval in oncology for homologous recombination repair deficient tumors including BRCA…”
Get full text

Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development by Gill, Sonja J, Wijnhoven, Paul W G, Fok, Jacqueline H L, Lloyd, Rebecca L, Cairns, Jonathan, Armenia, Joshua, Nikkilä, Jenni, Lau, Alan, Bakkenist, Christopher J, Galbraith, Susan M, Vens, Conchita, O'Connor, Mark J

“…Radiotherapy is an effective anticancer treatment, but combinations with targeted agents that maximize efficacy while sparing normal tissue are needed. Here,…”
Get full text

Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1 by Staniszewska, Anna D, Pilger, Domenic, Gill, Sonja J, Jamal, Kunzah, Bohin, Natacha, Guzzetti, Sofia, Gordon, Jacob, Hamm, Gregory, Mundin, Gill, Illuzzi, Giuditta, Pike, Andy, McWilliams, Lisa, Maglennon, Gareth, Rose, Jonathan, Hawthorne, Glen, Cortes Gonzalez, Miguel, Halldin, Christer, Johnström, Peter, Schou, Magnus, Critchlow, Susan E, Fawell, Stephen, Johannes, Jeffrey W, Leo, Elisabetta, Davies, Barry R, Cosulich, Sabina, Sarkaria, Jann N, O'Connor, Mark J, Hamerlik, Petra

“…We evaluated the properties and activity of AZD9574, a blood-brain barrier (BBB) penetrant selective inhibitor of PARP1, and assessed its efficacy and safety…”
Get full text

Abstract 1374: The novel PARP1-selective inhibitor AZD5305 has reduced hematological toxicity when compared to PARP1/2 inhibitors in pre-clinical models by Gill, Sonja J., Macdonald, Ruth, Pin, Carmen, Collins, Rob, Leonard, Emilyanne, Maglennon, Gareth, Pike, Andy, Cotton, Peter, Hawthorne, Glen, Pugh, Jordan, Sargeant, Rebecca, Sutton, Daniel, Atkinson, James, Jones, Stewart, Chinery, Sarah, Anderton, Mark

“…Current clinical poly (ADP-ribose) polymerase (PARP) inhibitors target both PARP1 and PARP2 and they all cause clinical cytopenias with varying severity…”
Get full text

Abstract 296: Structure-based and property-based drug design of AZD5305, a highly selective PARP1 inhibitor and trapper by Hande, Sudhir, Balazs, Amber, Degorce, Sébastien L., Embrey, Kevin, Ghosh, Avipsa, Gill, Sonja J., Gunnarsson, Anders, Illuzzi, Giuditta, Lane, Jordan, Larner, Carrie, Leo, Elisabetta, Madin, Andrew, McWilliams, Lisa, O'Connor, Mark J., Orme, Jonathan, Pachl, Fiona, Packer, Martin, Pike, Andy, Rawlins, Philip, Schimpl, Marianne, Staniszewska, Anna D., Zhang, Andrew, Zheng, Xiaolan, Johannes, Jeffrey W.

“…Since the approval of olaparib in 2014 for BRCA mutated (BRCAm) ovarian cancer, many PARP inhibitors have been developed and have seen widespread success…”
Get full text

Discovery of 5‑{4-[(7-Ethyl-6-oxo‑5,6-dihydro‑1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}‑N‑methyl­pyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs by Johannes, Jeffrey W, Balazs, Amber, Barratt, Derek, Bista, Michal, Chuba, Matthew D, Cosulich, Sabina, Critchlow, Susan E, Degorce, Sébastien L, Di Fruscia, Paolo, Edmondson, Scott D, Embrey, Kevin, Fawell, Stephen, Ghosh, Avipsa, Gill, Sonja J, Gunnarsson, Anders, Hande, Sudhir M, Heightman, Tom D, Hemsley, Paul, Illuzzi, Giuditta, Lane, Jordan, Larner, Carrie, Leo, Elisabetta, Liu, Lina, Madin, Andrew, Martin, Scott, McWilliams, Lisa, O’Connor, Mark J, Orme, Jonathan P, Pachl, Fiona, Packer, Martin J, Pei, Xiaohui, Pike, Andrew, Schimpl, Marianne, She, Hongyao, Staniszewska, Anna D, Talbot, Verity, Underwood, Elizabeth, Varnes, Jeffrey G, Xue, Lin, Yao, Tieguang, Zhang, Ke, Zhang, Andrew X, Zheng, Xiaolan

“…Poly-ADP-ribose-polymerase (PARP) inhibitors have achieved regulatory approval in oncology for homologous recombination repair deficient tumors including BRCA…”
Get full text